Brief: Akeso Announced FDA Clearance Of Ind For Cd47 Monoclonal Antibody (Ak117) In Combination With Azacitidine In Myelodysplastic Syndromes
28/09/2023 03:09
Sept 27 (Reuters) - Akeso 9926.HK :
* ANNOUNCED FDA CLEARANCE OF IND FOR CD47 MONOCLONAL
ANTIBODY
(AK117) IN COMBINATION WITH AZACITIDINE IN MYELODYSPLASTIC
SYNDROMES
* UPCOMING STUDY, KNOWN AS A RANDOMIZED, DOUBLE-BLIND,
GLOBAL
MULTI-CENTER PHASE II STUDY, IS SET TO BE CONDUCTED IN UNITED
STATES
Source text for Eikon: ID:nPn6czpr3a
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals